Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2010 - 2026)
Rigel Pharmaceuticals' quarterly Income from Continuing Operations came in at 8654000.0 in Q1 2026, down 24.39% year-on-year from 11446000.0 in Q1 2025, and down 96.77% quarter-over-quarter from 268065000.0 in Q4 2025.
Rigel Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 8654000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 24.39% year-over-year to 8654000.0; the trailing twelve-month figure through Mar 2026 stood at 364232000.0 (up 879.7% YoY), and the FY2025 full-year result was 367024000.0, up 1999.08% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8654000.0, down from 268065000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 268065000.0 in Q4 2025, with the low at 27445000.0 in Q1 2022.
- Average Income from Continuing Operations over 5 years is 18205823.53, with a median of 737000.0 recorded in 2023.
- Year-over-year, Income from Continuing Operations slumped 169.48% in 2022 and surged 5887.67% in 2025.
- Tracing RIGL's Income from Continuing Operations over 5 years: stood at 1401000.0 in 2022, then sank by 47.39% to 737000.0 in 2023, then jumped by 1845.86% to 14341000.0 in 2024, then soared by 1769.22% to 268065000.0 in 2025, then sank by 96.77% to 8654000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 8654000.0 (Q1 2026), 268065000.0 (Q4 2025), and 27900000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.65 Mn |
| Dec 31, 2025 | 268.07 Mn |
| Sep 30, 2025 | 27.90 Mn |
| Jun 30, 2025 | 59.61 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | 14.34 Mn |
| Sep 30, 2024 | 12.42 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | -8.25 Mn |
| Dec 31, 2023 | 737,000.00 |
| Sep 30, 2023 | -5.69 Mn |
| Jun 30, 2023 | -6.60 Mn |
| Mar 31, 2023 | -13.54 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | -19.04 Mn |
| Jun 30, 2022 | -13.49 Mn |
| Mar 31, 2022 | -27.45 Mn |
| Dec 31, 2021 | -22.60 Mn |
| Sep 30, 2021 | -20.95 Mn |
| Jun 30, 2021 | -13.79 Mn |
| Mar 31, 2021 | 39.50 Mn |
| Dec 31, 2020 | -19.24 Mn |
| Sep 30, 2020 | -14.17 Mn |
| Jun 30, 2020 | -17.58 Mn |
| Mar 31, 2020 | 21.24 Mn |
| Dec 31, 2019 | -17.20 Mn |
| Sep 30, 2019 | -11.49 Mn |
| Jun 30, 2019 | -20.61 Mn |
| Mar 31, 2019 | -17.60 Mn |
| Dec 31, 2018 | 3.23 Mn |
| Sep 30, 2018 | -23.77 Mn |
| Jun 30, 2018 | -25.56 Mn |
| Mar 31, 2018 | -24.39 Mn |
| Dec 31, 2017 | -25.87 Mn |
| Sep 30, 2017 | -17.66 Mn |
| Jun 30, 2017 | -19.15 Mn |
| Mar 31, 2017 | -16.05 Mn |
| Dec 31, 2016 | -15.68 Mn |
| Sep 30, 2016 | -22.63 Mn |
| Jun 30, 2016 | -13.53 Mn |
| Mar 31, 2016 | -17.46 Mn |
| Dec 31, 2015 | -12.69 Mn |
| Sep 30, 2015 | -6.73 Mn |
| Jun 30, 2015 | -13.91 Mn |
| Mar 31, 2015 | -18.19 Mn |
| Dec 31, 2014 | -22.32 Mn |
| Sep 30, 2014 | -20.99 Mn |
| Jun 30, 2014 | -25.39 Mn |
| Mar 31, 2014 | -22.30 Mn |
| Dec 31, 2013 | -16.88 Mn |
| Sep 30, 2013 | -23.82 Mn |
| Jun 30, 2013 | -22.77 Mn |
| Mar 31, 2013 | -25.57 Mn |
| Dec 31, 2012 | -25.49 Mn |
| Sep 30, 2012 | -25.46 Mn |
| Jun 30, 2012 | -24.74 Mn |
| Mar 31, 2012 | -23.17 Mn |
| Dec 31, 2011 | -25.79 Mn |
| Sep 30, 2011 | -17.93 Mn |
| Jun 30, 2011 | -21.47 Mn |
| Mar 31, 2011 | -20.78 Mn |
| Dec 31, 2010 | -19.60 Mn |
| Sep 30, 2010 | 50.43 Mn |
| Jun 30, 2010 | 27.03 Mn |